C4 Therapeutics (CCCC)

• Market cap: $250M
• 1 day: -1.55%
• 5 days: -2.31%
• 1 month: 2.42%
• 3 months: -6.96%
• 6 months: 67.11%
• Year to date: -30.6%
• 1 year: -46.07%
• 5 years: -91.25%
• 10 years: -90.04%
• Sector: Healthcare
• Industry: Biotechnology

About: C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Employees: 110